Among 26 patients receiving whole-breast irradiation after perioperative brachytherapy, 5-year local-relapse-free survival was 100% with no grade ≥3 toxicity.
No prospective trial has established the safety of combining partial breast irradiation with sentinel lymph node biopsy omission in early breast cancer.
Successful breast brachytherapy depends on careful patient selection, suitable cavity anatomy, sound implant geometry, accurate reconstruction, and rigorous treatment QA.
Twenty-five selected patients had 96% crude local control and no grade 3 toxicity after 26 Gy in five fractions.
Single-fraction GammaPod partial breast irradiation produced 12.1% fat necrosis and 4.1% symptomatic fat necrosis in a phase 2 trial.
Partial breast irradiation projected lower lifetime secondary lung cancer risk than whole breast irradiation in Korean early-stage breast cancer cohorts.
Five-fraction helical tomotherapy achieved favorable organ sparing, while the planning target volume-to-breast ratio was associated with higher ipsilateral breast dose.